CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 103 enrolled
Drug / intervention
Craniotomy +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04690348
NCT04690348Phase 2Active
CompareCT.gov

Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

Memorial Sloan Kettering Cancer Center·interventional·Posted Dec 30, 2020·Updated Jun 4, 2026

In Brief

A Phase 2 clinical trial evaluating Craniotomy and Cesium-131 brachytherapy for Recurrent Brain Metastases. Active but no longer recruiting, targeting 103 participants across 6 sites.

Detailed Summary

The purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Brain Metastases
CountriesUnited States
CollaboratorsGT Medical Technologies, Inc.

Timeline

Phase 2Active
2021202220232024202520262027
First PostedDec 30, 2020
Enrollment StartDec 24, 2020
Primary CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 5.5 years agoPrimary completion in 5 months

Interventions

Craniotomyprocedure

Craniotomy

Cesium-131 brachytherapyradiation

Intracavitary Cesium-131 brachytherapy